Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Has Average Target Price of $18.25

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $18.25.

Several brokerages recently commented on UNCY. B. Riley Financial restated a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Guggenheim reiterated a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. Finally, HC Wainwright dropped their price target on Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th.

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors have recently made changes to their positions in UNCY. Dimensional Fund Advisors LP bought a new position in shares of Unicycive Therapeutics during the 1st quarter worth about $940,000. Seven Fleet Capital Management LP grew its stake in shares of Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Unicycive Therapeutics in the 2nd quarter valued at about $248,000. Bank of America Corp DE grew its stake in shares of Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after buying an additional 29,378 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics in the 1st quarter valued at about $161,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Neutral Sentiment: Reported short interest was listed at 0 shares as of October 26, implying no measurable short-position overhang based on the provided data. However, the entry describes this as a large increase, so the figures may be inconsistent.
• Negative Sentiment: Multiple law firms reminded investors of a November 2 deadline to seek lead-plaintiff status in a securities class action covering purchases from December 29, 2025, through June 29, 2026. The repeated alerts increase attention around potential litigation costs, liability, and reputational risk. Glancy Prongay Wolke & Rotter deadline alert
• Negative Sentiment: The allegations center on statements that Unicycive reported its third-party manufacturer had made “significant progress” toward regaining FDA compliance without independently verifying that progress through an inspection. If substantiated, the claims could undermine confidence in the company’s regulatory and manufacturing disclosures. Levi & Korsinsky class-action alert
• Negative Sentiment: Noble Financial brokers reportedly reduced their earnings estimates for Unicycive, adding to concerns about the company’s outlook and reinforcing the stock’s speculative profile.

Unicycive Therapeutics Trading Down 8.0%

Shares of UNCY opened at $3.58 on Tuesday. The firm’s fifty day simple moving average is $4.68 and its two-hundred day simple moving average is $6.13. Unicycive Therapeutics has a 12 month low of $3.35 and a 12 month high of $8.74. The stock has a market capitalization of $99.70 million, a P/E ratio of -2.05 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.41. As a group, research analysts predict that Unicycive Therapeutics will post -1.16 EPS for the current fiscal year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.